Zoldonrasib Shows Early Strength in Previously Treated KRAS G12D NSCLC

oncodaily - KRAS G12D has long been one of the most frustrating targets in thoracic oncology. It is biologically important, clearly druggable in theory, and yet patients with KRAS G12D-mutant non-small cell […]

AI Summary: Investigational KRAS(ON) inhibitor zoldonrasib produced effective, durable responses in patients with advanced KRAS G12D–mutated non‑small‑cell lung cancer after prior therapy. Early‑phase data show meaningful tumour shrinkage and a manageable safety profile, offering a targeted option for a mutation long considered untargetable and breathing new life into KRAS drug development.


Experts on site: RAS inhibitors reshape NSCLC treatment landscape

Young Kwang Chae: The Future of RAS Therapy May Be in the Syringe Rather Than the Pill

2 months / oncodaily

Fawzi Abu Rous: Turning KRAS From “Undruggable” to a Targetable Driver in NSCLC

2 months / oncodaily

Ahmet Dirican: What Did Targeting KRAS Teach Us?

2 months / oncodaily

David Hong: The RAS Revolution Is Taking Off in NSCLC

2 months / oncodaily

Ariella Hanker: AACR26 Is “Still” the Year of RAS Inhibitors

2 months / oncodaily


Industry moves: BridgeBio reshuffles as KRAS race heats up

BridgeBio’s oncology spinoff swaps out CEOs as it seeks to accelerate KRAS work

2 months / endpoints / Drew Armstrong


On the AACR floor: zoldonrasib delivers durable G12D responses

Jonathan W. Riess on Zoldonrasib Effectiveness in Previously Treated KRAS G12D NSCLC – AACR

2 months / oncodaily

KRAS(ON) inhibitor zoldonrasib showed effective, durable responses in patients with advanced G12D-mutated lung cancer

2 months / medicalxpress

Zoldonrasib Shows Early Strength in Previously Treated KRAS G12D NSCLC

2 months / oncodaily

Investigational KRAS(ON) Inhibitor Zoldonrasib Showed Effective and Durable Responses in Patients With Advanced G12D-mutated Lung Cancer

2 months / aacr / Julia DeMalto


Perioperative and biomarker research reshapes precision care in NSCLC

Tumor-Draining Lymph Nodes in NSCLC: The Underused Frontier in Biomarker Discovery and Therapeutic Innovation

2 months / oncodaily

Risk factors for pathological invasiveness of non-mucinous invasive pulmonary adenocarcinoma with a maximum diameter of less than or equal to 3 cm in thin-section CT: a retrospective study

2 months / nature

MATISSE Trial Suggests CD39 Blockade May Deepen Pathologic Response in Resectable NSCLC

2 months / oncodaily

CheckMate 77T Biomarker Analysis Highlights ctDNA and Genomic Signals of Benefit With Perioperative Nivolumab in Resectable NSCLC

2 months / oncodaily


All Other Stories

KRAS G12C Inhibitors In NSCLC: From “Undruggable” To First-Line Contender

2 months / oncodaily

Erasca reports RAS cancer drug data after legal threat from Revolution

2 months / endpoints / Nicole DeFeudis

KIRHub Opens A New Repurposing Map For Kinase Inhibitors In Lung Cancer

2 months / oncodaily

Anirban Maitra: Breaking “Sub 2 Hour” Barrier of Oncology in Race to Drug KRAS

2 months / oncodaily

Nicholas Hornstein: Anticipating Resistance and Revolution Medicines’ Proactive Strategy for RAS Therapy

2 months / oncodaily

Nicholas Hornstein: Recent Data on RAS Therapies

2 months / oncodaily




Related Stories

EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 7 days

Long‑term Botensilimab+Balstilimab data show durable responses in MSS CRC / 13 days

Zanidatamab improves PFS over trastuzumab in HER2 GEA / 5 wks

MAGE‑A4/A8 TCR bispecific T‑cell engager shows activity in solid tumors / 5 wks

Teclistamab outperforms standard regimens in earlier-line relapsed myeloma / 6 wks

Common asthma drug may overcome immunotherapy resistance in cancers / 7 wks

Retifanlimab plus chemotherapy extends survival in advanced squamous anal cancer / 7 wks

StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Mergers and Acquisitions, CDC, Zoonotic Disease, Pancreatic Cancer and look for the RSS link.




↑

NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.